The MURANO Study: Final Analysis and Retreatment/Crossover Substudy Results of VenR for Patients with Relapsed/Refractory CLL.

Fixed-duration venetoclax-rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) in the Phase III MURANO trial resulted in superior progression-free survival and overall survival vs bendamustine-rituximab.